# OnCo record normunity (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/normunity/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "normunity" ;
  schema:name "Normunity"@en ;
  schema:alternateName "Normunity AccelCo, Inc."@en ;
  schema:description "Normunity develops antibody medicines that direct the immune system's T cells against tumours. Its lead, NRM-823, recognises a target found on several solid tumours but not on normal tissue, and is in an early trial."@en ;
  schema:url <https://onco.cc/companies/normunity/>, <https://normunity.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://normunity.com/>, <https://normunity.com/normunity-closes-75-million-series-b-financing-to-advance-lead-drug-program-into-the-clinic-and-broaden-pipeline-of-novel-anti-cancer-therapies-targeting-untapped-drug-mechanisms/>, <https://normunity.com/normunity-announces-first-patient-dosed-in-phase-1-clinical-study-of-nrm-823-a-t-cell-engager-against-a-novel-tumor-specific-target-in-patients-with-solid-tumors/>, <https://clinicaltrials.gov/study/NCT07182149> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/head-and-neck/>, <https://onco.cc/cancers/oesophageal-squamous-cell-carcinoma/>, <https://onco.cc/cancers/oesophageal-adenocarcinoma/>, <https://onco.cc/cancers/gastric/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/t-cell-engager/>, <https://onco.cc/technologies/bispecific-antibody/> .